When Is Adderall Back in Stock? The Honest 2026 Shortage Status Guide

As of June 2026, Adderall is not fully back in stock — the shortage that began in October 2022 remains officially active. Medfinder’s real-time pharmacy tracking, updated June 14, 2026, gives Adderall an availability score of 1% (Very Difficult to Find), based on 53,252 pharmacy checks in the preceding 30 days. The FDA’s original shortage notice from October 2022 has not been resolved, and both immediate-release and extended-release amphetamine mixed salts remain on the ASHP active shortage list as of mid-2026. Supply has improved modestly following DEA quota increases in late 2025 and early 2026, but higher-dose formulations in particular remain inconsistently available at a pharmacy level.

Table of Contents

Introduction

If you are trying to fill your Adderall prescription in 2026 and your pharmacy is out of stock, you are not alone — and you are not experiencing a temporary local glitch. The Adderall shortage is a national, multi-year, structurally-rooted supply failure that has now lasted more than three and a half years. Every few months since October 2022, patients have heard from pharmacists, clinicians, and news reports that supply is “improving” and relief is “coming soon” — and every few months, the shortage has continued.

This article gives you the honest, up-to-date status as of June 2026, a formulation-by-formulation breakdown of what is currently available, where the regulatory situation stands, and — most importantly — a clear, actionable strategy for finding stock right now and managing your treatment until the shortage resolves.

Current Status: Is Adderall Back in Stock? (June 2026)

The definitive answer requires separating what is officially improving from what patients are experiencing on the ground:

Official Status

FDA Drug Shortages Database: Multiple amphetamine mixed salt formulations — both IR and XR — remain listed on the FDA’s official shortage database as of June 2026. The FDA’s original Adderall shortage notice, first issued in October 2022, has not been closed
ASHP Shortage List: Amphetamine Mixed Salts IR and XR remain active entries on the American Society of Health-System Pharmacists’ shortage list as of mid-2026
Amneal extended-release: 10 mg and 15 mg remain listed as active shortage items
Multiple manufacturers: Manufacturers including Rhodes, Amneal, and Camber reported extended back orders for certain extended-release capsules into early 2026; Teva reported constrained IR supplies with some recovery estimates pushed to late January–February 2026

Real-Time Patient-Level Data

Medfinder’s shortage tracker — updated June 14, 2026, based on 53,252 pharmacy checks — presents the clearest ground-level picture:

Availability score: 1% (categorised as “Very Difficult to Find”)
5,875 patients searched for Adderall on Medfinder in the preceding 30 days
Last in-stock report: June 13, 2026 — confirming stock exists somewhere, but is extremely scarce
The tracker refreshes every 6 hours from aggregated pharmacy check outcomes

In practical terms: Adderall is available in the US in June 2026, but finding it at any given pharmacy on a given day requires active searching, not the assumption of availability.

Which Formulations Are Hardest to Find vs. Easier to Find

Not all Adderall formulations are equally affected — the shortage has hit specific doses and release types harder:

Hardest to Find (Most Affected)

Adderall XR 15 mg, 20 mg, and 25 mg (extended-release capsules)
Adderall IR 20 mg and 30 mg (immediate-release tablets, higher doses)
Generic Adderall XR — has been the most consistently cited out-of-stock product since mid-2022
ASHP lists the 20 mg and 30 mg XR capsules as on back order from at least one manufacturer, with release dates that were estimated for mid-to-late May 2026 per the last ASHP update

More Available (Relatively)

Lower-dose IR formulations (5 mg, 7.5 mg, 10 mg) tend to have better availability than higher doses. As a University of Utah Health pharmacist noted: “The shorter-acting products are in somewhat better supply”
Brand-name Adderall XR — brand formulations from Teva have been more consistently available than generic XR versions for most of the shortage period
Teva-manufactured generic — Teva remains the most consistent generic manufacturer; pharmacies stocking Teva-manufactured products have been more reliably supplied
Adderall IR 5 mg and 10 mg — the lowest-demand doses have been the least shortage-affected

Regulatory Updates: What Has Changed in 2025–2026

DEA Quota Increases (The Most Significant Development)

The most meaningful regulatory action since the shortage began occurred in the second half of 2025:

October 2025: The DEA raised the 2025 Aggregate Production Quota (APQ) for d-amphetamine from 21.2 million grams to 26.5 million grams — a ~25% increase, the first quota increase since 2021. Lisdexamfetamine quotas were raised ~22%; methylphenidate quotas raised ~9%
Early 2026: The DEA finalised 2026 APQs with an additional ~14% increase above the originally proposed level for d,l-amphetamine, following over 5,000 public comments from patients and advocacy groups
The 2026 APQ increase was specifically cited as being above the original proposal following patient advocacy

Why this hasn’t fully resolved the shortage:Quota increases set new production ceilings — but manufacturing ramp-up takes months. With Mylan and Zydus having permanently exited the market, the increased quota is distributed across a smaller manufacturer base than existed when the shortage began. The production gains are real but gradual — not an immediate pharmacy-level fix.

New Manufacturer Entry

US Pharma Windlas recently began distribution of Adderall product, adding a new manufacturer to the supply base. This represents the first new market entrant since the shortage began and is a structural positive for long-term supply
SpecGx (a generic Vyvanse manufacturer) had all dosages back in stock after most were on back order the prior year
The FDA noted its Drug Shortages Database “now lists nine manufacturers with ADHD medications back in stock, up from six” earlier

The “Improving But Not Resolved” Assessment

As of the most recent tracking data, independent sources consistently characterise the shortage as improving in aggregate but unresolved in patient experience:

“The shortage is improving but not resolved” — ISSUP summary of current status
“As of mid-2026, the Adderall shortage that began in October 2022 remains active” — Klarity Health, updated June 1, 2026
“Adderall shortages persist into 2026 despite a DEA quota increase. Patients face uneven access” — Thunder Report, January 2026
“Higher-dose formulations are typically the last to normalize because manufacturers prioritize the highest-volume items first” — Klarity Health

When Will Adderall Be Fully Back in Stock? The Honest Forecast

The blunt answer: there is no confirmed date and every prediction made since 2022 has been wrong. Here is what the trajectory actually looks like:

A pattern of missed recovery estimates:

Early 2023: “Relief coming in spring 2023” — not resolved
Mid-2023: “Supply stabilising by summer” — not resolved
Late 2023: “No end in sight” — acknowledged by major outlets
2024: Quota increases promised — delays in implementation
Late 2025: DEA quota raised 25% — improvement but not resolution
Mid-2026: Still listed on FDA shortage database; 1% availability score

What will it take to fully resolve the shortage:Experts and regulators have converged on a clear list of conditions that must be met for the shortage to end:

Manufacturer production must ramp up to utilise the newly increased DEA quotas
New manufacturers must enter and stabilise supply (Windlas entry is a positive signal)
API supply chains must normalise after COVID-era disruptions
Market equilibrium must be reached between telehealth-driven demand and supply capacity
Higher-dose formulations must work through their back-order queues — manufacturers address highest-volume items first

Most realistic timeline, based on current trajectory:

Low-dose IR (5–10 mg): Substantially improved already; intermittent rather than persistent shortages
Higher-dose IR (20–30 mg): Gradual improvement throughout 2026; likely approaching normalisation by late 2026
XR formulations (15–25 mg): The longest-running shortage component; manufacturers’ back-order estimates push into mid-to-late 2026
Full market normalisation: No confirmed date; patient advocates and pharmacists caution that “intermittent shortages may continue into late 2026”

What to Do Right Now If You Can’t Find Adderall

Step 1 — Check Real-Time Stock Before Going Anywhere

Do not walk into a pharmacy without first confirming stock:

Medfinder (medfinder.com/shortage-tracker/adderall) — real-time stock tracker refreshed every 6 hours; locates Adderall in stock for 2,000+ patients per month. Enter your medication (e.g., “Adderall XR 20mg”), your ZIP code, and wait for results
GoodRx pharmacy locator — shows stock availability and pricing across nearby pharmacies
Phone the specific pharmacy — if Medfinder shows stock, call to confirm before presenting your prescription; stock can deplete between checks

Step 2 — Target the Right Pharmacy Types

Not all pharmacies are equal in shortage conditions:

Independent pharmacies — most consistently stocked; order through different wholesaler relationships; pharmacists often call other independents on your behalf
Costco Pharmacy — warehouse-club purchasing relationships give it supply advantages; no membership required; among lowest cash prices
Grocery chain pharmacies (HEB, Kroger, Publix, Safeway) — less ADHD prescription volume means their DEA quota allocations face less competitive pressure
Avoid calling multiple CVS and Walgreens branches — they purchase from the same wholesalers; if one is out, most others will be too

Step 3 — Be Specific When Calling Pharmacies

Ask clearly and specifically:

“Do you have [generic/brand] Adderall [IR/XR] [dose]mg in stock right now?”
“Which manufacturer is your current Adderall from?” — Teva tends to be more reliable
Call during off-peak hours — mid-weekday mornings and Saturdays — when pharmacists have time to properly check

Step 4 — Use the One-Time Prescription Transfer If Needed

If your e-prescription was sent to a pharmacy that is out of stock:

Call your current pharmacy and ask them to transfer your electronic prescription to the pharmacy that has stock
Under the DEA’s 2023 rule, this is permitted once, directly between licensed pharmacists
For paper prescriptions, your prescriber must cancel and reissue to the new pharmacy

Step 5 — Talk to Your Prescriber About Alternatives Now, Not When You Run Out

Do not wait until you are completely out of medication before exploring alternatives:

Amphetamine-based alternatives most likely to be available:

Vyvanse (lisdexamfetamine, brand) — same active compound; DEA quota raised 22% in 2025; often more available than generic Adderall XR
Adzenys XR-ODT — amphetamine XR orally disintegrating tablet; closest pharmacological equivalent to Adderall XR; often the first substitute recommended by prescribers during shortage
Dyanavel XR — extended-release amphetamine oral suspension; different formulation, same pharmacology
Dextroamphetamine (Dexedrine/generic) — the primary active isomer of Adderall; separate shortage dynamics from mixed salts
Evekeo — mixed amphetamine salts with slightly different ratio; may have better availability than standard Adderall

If amphetamine-based options are all unavailable:

Methylphenidate-based medications (Ritalin, Concerta, Focalin, Jornay PM, Quillichew) — different drug class, same therapeutic category; quota increased ~9% in 2025; a common interim bridge
Non-stimulants (Strattera/atomoxetine, Qelbree/viloxazine) — not Schedule II; no shortage risk; not equivalent in rapid effect but effective for ADHD management

How to Monitor the Shortage Going Forward

Staying informed prevents being caught off-guard by monthly stock availability changes:

Medfinder Shortage Tracker — bookmark medfinder.com/shortage-tracker/adderall for availability scores updated every 6 hours
FDA Drug Shortages Database — go to fda.gov/drugs/drug-safety-and-availability/drug-shortages; search “amphetamine mixed salts” to check manufacturer-specific estimated resolution dates
ASHP Drug Shortage Database — ashp.org drug shortage listings include manufacturer-specific back-order notes and estimated recovery dates
r/ADHD and r/adhdwomen on Reddit — active, real-time crowdsourced pharmacy availability data by city; some of the most current ground-level shortage intelligence available
Start refill process 2 weeks early — build in lead time for shortage-related delays

A Note on False “Back in Stock” Signals

A recurring pattern since 2022 is premature announcements that the shortage is resolved or nearly over. These signals can come from:

A single manufacturer resolving their individual shortage — which improves national supply marginally but does not mean your pharmacy will have stock
FDA removing one formulation from the shortage list — while others remain listed
Improved availability of one dose strength — while other doses remain critically short
Local or regional variation — patients in some markets may find stock consistently while others in different regions cannot

The Medfinder 1% availability score as of June 14, 2026, provides the most accurate current picture: stock exists somewhere, but finding it requires active effort. Until the FDA officially closes its shortage notice for all amphetamine mixed salt formulations and major pharmacies stock Adderall without patients needing to hunt, the shortage has not ended.

FAQ — When Is Adderall Back in Stock?

Is Adderall back in stock in 2026?Partially — supply has improved compared to 2022–2023, but the shortage remains active as of June 2026. Medfinder’s tracker gives Adderall a 1% availability score (Very Difficult to Find) based on 53,252 pharmacy checks, and both IR and XR formulations remain on the FDA and ASHP shortage lists.

When will Adderall be back in stock?There is no confirmed date. DEA quota increases in late 2025 and early 2026 are expected to gradually improve availability, with higher-dose XR formulations potentially normalising by late 2026 — but the shortage has no confirmed end date and multiple predictions since 2022 have not materialised on schedule.

Which Adderall is hardest to find right now?Adderall XR 15 mg, 20 mg, and 25 mg; Adderall IR 20 mg and 30 mg — these higher-dose formulations are the most affected. Lower-dose IR formulations (5–10 mg) and brand-name Adderall XR are comparatively more available.

How do I find Adderall in stock near me?Use Medfinder’s real-time tracker (medfinder.com) before going to any pharmacy — it checks inventory at pharmacies near your ZIP code and refreshes every 6 hours. GoodRx’s pharmacy locator also shows stock-level data. Once you confirm stock, call to verify before presenting your prescription.

What should I do if I can’t find Adderall?Contact your prescriber to discuss alternatives — Vyvanse, Adzenys XR-ODT, dextroamphetamine, or methylphenidate-based medications for interim coverage. Target independent pharmacies, Costco, and grocery chain pharmacies over major chains. Request a one-time prescription transfer if your e-prescription is already at a pharmacy that is out of stock.

Is Adderall XR back in stock?Not consistently — Adderall XR (generic) remains one of the hardest-to-find formulations as of mid-2026, with ASHP listing multiple XR capsule strengths on active back order. Brand-name Adderall XR has been more consistently available than generic XR throughout the shortage.

Has the DEA done anything about the Adderall shortage?Yes — the DEA raised the 2025 production quota for d-amphetamine by approximately 25% in October 2025, and finalised 2026 quotas at an additional ~14% above originally proposed levels. These are the first meaningful quota increases since 2021. However, manufacturing ramp-up takes time and market-level effects are gradual.

The Bottom Line

As of June 15, 2026, Adderall is not back in stock in any meaningful, consistent sense — Medfinder’s availability score of 1%, based on over 53,000 pharmacy checks, tells the clearest story. The FDA’s original shortage notice from October 2022 remains open; both IR and XR formulations remain on active shortage lists; and patients are still routinely unable to fill prescriptions at their usual pharmacy. The DEA’s 2025–2026 quota increases are a genuine regulatory step forward — but the manufacturing ramp-up lag, reduced supplier base after multiple manufacturer exits, and persistently elevated demand mean full resolution is a gradual process with no confirmed endpoint. The practical response for patients is proactive rather than passive: use real-time stock tools, target the right pharmacy types, start the refill process two weeks early, and have an honest conversation with your prescriber now about clinically equivalent alternatives — before you run out, not after.

When is Adderall back in stock Hobart
When is Adderall back in stock Devonport
When is Adderall back in stock Launceston
When is Adderall back in stock Tasmania
When is Adderall back in stock Victoria
When is Adderall back in stock Queensland
When is Adderall back in stock Canberra
When is Adderall back in stock Australian Capital Territory
When is Adderall back in stock South Australia
When is Adderall back in stock New South Wales
When is Adderall back in stock Darwin
When is Adderall back in stock Ghan
When is Adderall back in stock Northern Territory
When is Adderall back in stock Australia
When is Adderall back in stock Austria
When is Adderall back in stock Germany
When is Adderall back in stock United Kingdom
When is Adderall back in stock Sweden
When is Adderall back in stock Denmark
When is Adderall back in stock Norway
When is Adderall back in stock Finland
When is Adderall back in stock Iceland
When is Adderall back in stock Netherlands
When is Adderall back in stock Spain
When is Adderall back in stock Ireland
When is Adderall back in stock Switzerland